NYSE:ALC

Alcon (ALC) Stock Price, News & Analysis

$81.29
+0.94 (+1.17%)
(As of 02:27 PM ET)
Today's Range
$80.63
$81.59
50-Day Range
$77.57
$88.15
52-Week Range
$69.44
$88.23
Volume
337,930 shs
Average Volume
878,731 shs
Market Capitalization
$40.08 billion
P/E Ratio
41.47
Dividend Yield
N/A
Price Target
$91.22

Alcon MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
12.1% Upside
$91.22 Price Target
Short Interest
Healthy
0.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of Alcon in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.77%
From $3.05 to $3.47 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.83 out of 5 stars

Medical Sector

210th out of 905 stocks

Ophthalmic Goods Industry

2nd out of 7 stocks

ALC stock logo

About Alcon Stock (NYSE:ALC)

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

ALC Stock Price History

ALC Stock News Headlines

Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).
Star Surgical Shines as U.S. Outlook Improves for 2024 (ALC)
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Alcon is Now Oversold (ALC)
See More Headlines
Receive ALC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alcon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
5/09/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Health Care Facilities
CUSIP
04544X30
Employees
25,000
Year Founded
1945

Price Target and Rating

Average Stock Price Target
$91.22
High Stock Price Target
$100.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+13.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
14 Analysts

Profitability

Net Income
$974 million
Pretax Margin
8.80%

Debt

Sales & Book Value

Annual Sales
$9.46 billion
Cash Flow
$5.30 per share
Book Value
$41.83 per share

Miscellaneous

Free Float
N/A
Market Cap
$39.62 billion
Optionable
Optionable
Beta
0.92

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. F. Michael Ball (Age 69)
    Executive Chairman
    Comp: $1.17M
  • Mr. Arthur B. Cummings M.D. (Age 62)
    Executive Director
    Comp: $284.68k
  • Mr. David J. Endicott (Age 59)
    CEO & Director
    Comp: $4.82M
  • Mr. Timothy C. Stonesifer (Age 57)
    Chief Financial Officer
  • Margaret Buckley
    Chief Accounting Officer
  • Dr. Franck Leveiller
    Senior VP, Head of Global R&D and Chief Scientific Officer
  • Ms. Sue-Jean Lin (Age 65)
    Senior VP and Chief Information & Transformation Officer
  • Mr. Royce R. Bedward (Age 58)
    Senior VP, General Counsel & Corporate Secretary
  • Ms. Kimberly Martin (Age 49)
    Senior VP, Chief HR Officer & Corporate Communications
  • Mr. Laurent Attias (Age 56)
    Head of Corporate Development, Strategy, BD&L and M&A

ALC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alcon stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alcon in the last year. There are currently 2 sell ratings, 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALC shares.
View ALC analyst ratings
or view top-rated stocks.

What is Alcon's stock price target for 2024?

14 brokers have issued 1-year price targets for Alcon's shares. Their ALC share price targets range from $65.00 to $100.00. On average, they expect the company's stock price to reach $91.22 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price.
View analysts price targets for ALC
or view top-rated stocks among Wall Street analysts.

How have ALC shares performed in 2024?

Alcon's stock was trading at $78.12 at the beginning of 2024. Since then, ALC stock has increased by 4.1% and is now trading at $81.36.
View the best growth stocks for 2024 here
.

Are investors shorting Alcon?

Alcon saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 3,330,000 shares, a decrease of 22.9% from the March 31st total of 4,320,000 shares. Based on an average daily volume of 917,700 shares, the days-to-cover ratio is presently 3.6 days. Currently, 0.7% of the shares of the stock are short sold.
View Alcon's Short Interest
.

When is Alcon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ALC earnings forecast
.

How were Alcon's earnings last quarter?

Alcon Inc. (NYSE:ALC) issued its earnings results on Tuesday, February, 27th. The healthcare company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.02. The healthcare company had revenue of $2.33 billion for the quarter, compared to analyst estimates of $2.34 billion. Alcon had a net margin of 10.30% and a trailing twelve-month return on equity of 6.75%. The firm's revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.42 earnings per share.

What guidance has Alcon issued on next quarter's earnings?

Alcon issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 3.000-3.100 for the period, compared to the consensus EPS estimate of 3.040. The company issued revenue guidance of $9.9 billion-$10.1 billion, compared to the consensus revenue estimate of $10.0 billion.

What is Greg D. Wight's approval rating as Alcon's CEO?

6 employees have rated Alcon Chief Executive Officer Greg D. Wight on Glassdoor.com. Greg D. Wight has an approval rating of 100% among the company's employees. This puts Greg D. Wight in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alcon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alcon investors own include AT&T (T), Novartis (NVS), Verizon Communications (VZ), International Business Machines (IBM), Intel (INTC), Pfizer (PFE), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Exxon Mobil (XOM) and AbbVie (ABBV).

Who are Alcon's major shareholders?

Alcon's stock is owned by many different institutional and retail investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (1.66%), Bank of New York Mellon Corp (1.15%), Sustainable Growth Advisers LP (0.80%), AMF Tjanstepension AB (0.70%), Allspring Global Investments Holdings LLC (0.55%) and Assenagon Asset Management S.A. (0.37%).

How do I buy shares of Alcon?

Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alcon have any subsidiaries?
The following companies are subsidiares of Alcon: Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.
Read More
This page (NYSE:ALC) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners